The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 528 KB) and Technical Notes (PDF, 794 KB) pages.


Download and Print: Download Printer-friendly PDF Download data


Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2012-2016
Females by Race

Histologya All Races White Black Asian/
Pacific Islander
American Indian
/Alaska Nativeb
Hispanicc
Count Percent Count Percent Count Percent Count Percent Count Percent Count Percent
Carcinoma 21,655 97.7% 15,729 97.9% 3,285 96.4% 2,076 98.4% 153 97.5% 4,791 98.1%
Epidermoid carcinomad (8050-8131) 14,299 64.5% 10,041 62.5% 2,507 73.5% 1,364 64.7% 111 70.7% 3,220 65.9%
Squamous cell carcinoma (8070) 10,401 46.9% 7,260 45.2% 1,863 54.6% 990 46.9% 89 56.7% 2,230 45.7%
Squamous cell, keratinizing (8071) 1,393 6.3% 965 6.0% 279 8.2% 120 5.7% - - 340 7.0%
Squamous cell, non-keratinizing (8072) 1,783 8.0% 1,318 8.2% 247 7.2% 176 8.3% - - 479 9.8%
Squamous cell, Microinvasive (8076) 359 1.6% 255 1.6% 53 1.6% 32 1.5% - - 81 1.7%
Other (8050-8069, 8073-8075,8077-8131) 363 1.6% 243 1.5% 65 1.9% 46 2.2% - - 90 1.8%
Adenocarcinomae 6,402 28.9% 5,045 31.4% 592 17.4% 610 28.9% 38 24.2% 1,384 28.3%
Adenocarcinoma, NOS (8140) Adenosquamous (8560,8570) 3,250 14.7% 2,574 16.0% 286 8.4% 306 14.5% 17 10.8% 690 14.1%
707 3.2% 513 3.2% 94 2.8% 90 4.3% - - 179 3.7%
Other adenocarcinomasf 2,445 11.0% 1,958 12.2% 212 6.2% 214 10.1% - - 515 10.5%
Other specific carcinomasg 431 1.9% 288 1.8% 87 2.6% 48 2.3% - - 79 1.6%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022) 523 2.4% 355 2.2% 99 2.9% 54 2.6% - - 108 2.2%
Sarcomah 103 0.5% 64 0.4% 30 0.9% - - - - 20 0.4%
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539) 256 1.2% 165 1.0% 58 1.7% 22 1.0% - - 38 0.8%
Unspecified (8000-8005) 153 0.7% 105 0.7% 36 1.1% - - - - 35 0.7%
Total 22,167 100.0% 16,063 100.0% 3,409 100.0% 2,109 100.0% 157 100.0% 4,884 100.0%

Footnotes:

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts). Percents may not sum to 100 due to rounding.

a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

e Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

f Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.

g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562, 8575,8580-8671.

h Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Page Navigation: << Previous Next >>


The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.